PortfoliosLab logo
Autolus Therapeutics plc (AUTL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US05280R1005

CUSIP

05280R100

IPO Date

Jun 22, 2018

Highlights

Market Cap

$465.75M

EPS (TTM)

-$0.88

Total Revenue (TTM)

$9.01M

Gross Profit (TTM)

-$24.52M

EBITDA (TTM)

-$235.74M

Year Range

$1.11 - $5.00

Target Price

$9.97

Short %

5.24%

Short Ratio

4.48

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Autolus Therapeutics plc

Popular comparisons:
AUTL vs. ATRA
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Autolus Therapeutics plc (AUTL) returned -25.53% year-to-date (YTD) and -58.23% over the past 12 months.


AUTL

YTD

-25.53%

1M

29.63%

6M

-47.29%

1Y

-58.23%

3Y*

-13.88%

5Y*

-32.53%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

3.96%

6M

-2.00%

1Y

12.02%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of AUTL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.96%-21.72%-10.40%-9.03%24.11%-25.53%
2024-6.52%-0.33%6.33%-42.32%13.86%-16.95%34.77%-16.20%-7.63%-7.16%-1.48%-29.22%-63.51%
202313.16%-9.77%-5.15%-1.63%71.82%-23.47%35.71%-0.62%-27.41%21.03%51.77%50.47%238.95%
2022-23.12%-6.27%11.50%-25.18%-12.18%3.28%-1.41%18.28%-35.15%33.18%-7.37%-28.03%-63.39%
2021-17.79%-12.38%-11.02%1.57%13.92%0.15%-19.88%29.14%-4.66%-14.81%15.23%-19.28%-41.95%
2020-25.61%-16.70%-26.77%57.26%32.91%28.04%-17.65%11.14%-20.65%-7.13%-2.96%-14.78%-32.27%
2019-19.58%3.56%15.06%-16.81%-21.20%-21.96%-4.22%-32.88%20.00%-3.62%25.31%-12.00%-59.81%
20187.16%-12.36%26.49%3.27%-7.08%36.91%-15.84%31.36%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AUTL is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AUTL is 1313
Overall Rank
The Sharpe Ratio Rank of AUTL is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of AUTL is 1212
Sortino Ratio Rank
The Omega Ratio Rank of AUTL is 1515
Omega Ratio Rank
The Calmar Ratio Rank of AUTL is 1414
Calmar Ratio Rank
The Martin Ratio Rank of AUTL is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Autolus Therapeutics plc Sharpe ratios as of Jun 2, 2025 (values are recalculated daily):

  • 1-Year: -0.74
  • 5-Year: -0.42
  • All Time: -0.39

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Autolus Therapeutics plc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Autolus Therapeutics plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Autolus Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Autolus Therapeutics plc was 97.63%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Autolus Therapeutics plc drawdown is 96.35%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.63%Nov 12, 20181611Apr 10, 2025
-27.36%Sep 11, 201823Oct 11, 201820Nov 8, 201843
-24.83%Jun 27, 201812Jul 13, 201821Aug 13, 201833
-5.65%Aug 20, 20184Aug 23, 201810Sep 7, 201814
-0.82%Aug 14, 20181Aug 14, 20181Aug 15, 20182
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Autolus Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Autolus Therapeutics plc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -4.2%.


-0.80-0.60-0.40-0.200.0020212022202320242025
-0.26
-0.25
Actual
Estimate

Valuation

The Valuation section provides an overview of how Autolus Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AUTL relative to other companies in the Biotechnology industry. Currently, AUTL has a P/S ratio of 51.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AUTL in comparison with other companies in the Biotechnology industry. Currently, AUTL has a P/B value of 1.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items